MLICM
TERN

Metropolitan Life Insurance Company (MetLife)’s Terns Pharmaceuticals TERN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,395
Closed -$15.7K – 1903
2024
Q1 		$15.7K Hold
2,395
– – ﹤0.01% 1964
2023
Q4 		$15.5K Hold
2,395
– – ﹤0.01% 2025
2023
Q3 		$12K Hold
2,395
– – ﹤0.01% 2134
2023
Q2 		$21K Buy
+2,395
New +$27.9K ﹤0.01% 1904

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TERN Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Terns Pharmaceuticals (TERN) in Q2 2024, closing a stake of 2,395 shares — an estimated $15.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TERN in Q2 2023 and held it in 4 quarters. The position peaked at $21K in Q2 2023. 126 funds tracked by Wall St. Rank hold TERN as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Terns Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,395 Terns Pharmaceuticals shares in Q2 2024, an estimated $15.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Terns Pharmaceuticals position peaked at $21K in Q2 2023.
  • 126 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.